Department of Pediatrics, University of Maryland, School of Medicine, 685 West Baltimore Street, Room 480, Baltimore, MD 21201, USA.
Expert Rev Vaccines. 2013 Aug;12(8):933-53. doi: 10.1586/14760584.2013.815412.
Dengue is among the most prevalent and important arbovirus diseases of humans. To effectively control this rapidly spreading disease, control of the vector mosquito and a safe and efficacious vaccine are critical. Despite considerable efforts, the development of a successful vaccine has remained elusive. Multiple factors have complicated the creation of a successful vaccine, not the least of which are the complex, immune-mediated responses against four antigenically distinct serotypes necessitating a tetravalent vaccine providing long-lasting protective immunity. Despite the multiple impediments, there are currently many promising vaccine candidates in preclinical and clinical development. Here, the recent advances in dengue virus vaccine development are reviewed and the challenges associated with the use of these vaccines as a public health tool are briefly discussed.
登革热是人类中最普遍和最重要的虫媒病毒病之一。为了有效控制这种迅速传播的疾病,控制病媒蚊子和安全有效的疫苗至关重要。尽管付出了巨大努力,但成功疫苗的开发仍然难以实现。多种因素使得成功疫苗的研发变得复杂,其中最复杂的是针对四个抗原不同血清型的复杂免疫介导反应,这需要一种四价疫苗来提供持久的保护性免疫。尽管存在多重障碍,但目前有许多有前途的候选疫苗正在临床前和临床开发中。本文综述了登革热病毒疫苗开发的最新进展,并简要讨论了将这些疫苗用作公共卫生工具所面临的挑战。